Ad is loading...
MENU

RGLS Stock Regulus Therapeutics (RGLS, $1.43) entered Downtrend as Momentum indicator drops below 0 level on Nov 15, 2024

A.I.dvisor
at Tickeron.com
Loading...
RGLS - Regulus Therapeutics
Momentum signal
Bearish Trend
Odds of DOWN Trend
Tickeron
Momentum signal
Price: $1.43
Daily change: -$0.07 (-4.67%)
Daily volume: 261.9K
Capitalization: $93.7M
Industry: Biotechnology
This indicator may be signaling that RGLS's price has further to drop, since it fell below its price logged 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options. A.I.dvisor backtested 87 similar cases where RGLS's Momentum Indicator fell below the 0 level, and of them led to a successful outcome. Odds of Success:

Momentum Indicator for RGLS turns negative, indicating new downward trend

RGLS saw its Momentum Indicator move below the 0 level on November 15, 2024. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 87 similar instances where the indicator turned negative. In of the 87 cases, the stock moved further down in the following days. The odds of a decline are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

RGLS moved below its 50-day moving average on November 13, 2024 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where RGLS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for RGLS entered a downward trend on November 05, 2024. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 70 cases where RGLS's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for RGLS just turned positive on November 12, 2024. Looking at past instances where RGLS's MACD turned positive, the stock continued to rise in of 47 cases over the following month. The odds of a continued upward trend are .

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where RGLS advanced for three days, in of 250 cases, the price rose further within the following month. The odds of a continued upward trend are .

RGLS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.079) is normal, around the industry mean (14.849). P/E Ratio (0.000) is within average values for comparable stocks, (95.928). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.788). RGLS has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.012). P/S Ratio (0.000) is also within normal values, averaging (211.128).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. RGLS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RGLS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
RGLS
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of pharmaceutical products

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Pharmaceuticals Other
Address
4224 Campus Point Court
Phone
+1 858 202-6300
Employees
30
Web
https://www.regulusrx.com